Building a Better Veterinary Diagnostics Business – Thermo Fisher and Zoetis

Served by myriad companies differentiated by product strengths, the veterinary diagnostics market has had few dedicated or comprehensive market players outside of IDEXX Laboratories. The market leader serves the companion animal veterinary clinic market – offering veterinary platforms for clinical chemistry, hematology, coagulation, urinalysis, critical care, and routine infectious disease testing – and food animal testing market.

Sale of a Third Siemens Healthcare Unit: Will The Company Stay in IVD?

If the recent sale of its audiology unit was the only such move made this year, there would be no question about the place of Siemens in the healthcare market. But this recent sale is one of three. Siemens is the third largest company in IVD, according to Kalorama Information's biennial survey of the IVD market, with 5.5 billion in IVD revenues last year. In July Siemens agreed to sell its clinical microbiology business to Beckman Coulter, a subsidiary of Danaher Corp.

Checking Up on Patient Monitoring: Medtronic and Covidien

Medtronic’s roughly $43 billion acquisition and merger with Covidien created the world’s second-largest medical device company. The deal had significant implications in terms of enhanced market presence and company financials with the Medtronic’s move to Covidien’s Ireland home. The deal also made Medtronic-Covidien a stronger leading player in the advanced remote patient monitoring system market.

How and Where IVD Will Find Growth in the Global POL Market – Part 2

The global POL market is experiencing a convergence in terms of test demand. Rising and established living standards in the developed and developing world respectively have created common health issues such as diabetes, hypertension, heart disease, and obesity. Demand is consequently fast growing for POL tests such as lipid panels, HbA1c, and cardiac markers. Physician office lab market players in one region can now expect to find comparable reception for their products abroad.


Ebola Diagnosis on the Fast Track

In addition to expedited device approvals for diseases without effective existing treatments, the FDA has also fast-tracked Ebola tests under its emergency responsibilities in the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA). The FDA’s announcement of emergency use authorizations (EUAs) for Ebola test kits beginning in August 2014 promoted the development of several tests by both public organizations and private industry.


Subscribe to Kalorama Information Home RSS